Все публикации

0:08:40

Are There Resources for Melanoma Patients?

0:05:57

Welcome & Opening Remarks

0:13:55

Immunotherapy Combinations as First-Line Therapy

0:25:55

NeoAdjuvant & Adjuvant Therapy: Questions Getting Answered

0:26:31

Circulating Tumor DNA: Liquid Gold

0:26:31

Clinical Trial Options – New Data, Future Therapies

0:28:40

Cellular therapy: TIL Tomorrow and Further

0:22:23

Radiation Therapy in Melanoma, Novel Paradigms

0:16:16

Seeking Answers: Ocular Melanoma Making Strides

0:23:40

Update on Surgery and Predictive Testing for Early Stage Melanoma

0:21:16

Adjuvant and Neoadjuvant Therapy for Stage II and III Melanoma

0:31:19

What’s the Best Approach to Treating Stage IV Melanoma?

3:41:43

The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate

3:07:03

Oregon Health & Science University

3:16:40

UPMC Hillman Cancer Center | April 1, 2023

0:07:34

AIM at Melanoma Patient Resources

0:21:06

The Latest Approaches for Brain Metastases

0:20:01

TIL Therapies

0:16:59

Targeted Therapy-BRAF Inhibitors and Beyond

0:26:05

Neoadjuvant Therapy and Adjuvant Therapy (pre and post-surgery) for Melanoma

0:03:42

Opening Remarks

0:05:38

Welcoming Remarks

0:20:49

Life After Treatment: A Conversation About the Side Effects of Immunotherapy vs Targeted Therapy

0:11:34

Clinical Trials in Melanoma—Lessons From the Pandemic